NuVasive (NSDQ:NUVA) said today it launched its AttraX scaffold ceramic-collagen bone graft in the US, touting that the scaffold’s surface has been shown to increase bone formation for faster fusion than standard ceramic bone grafts.
The San Diego-based company claims that the Attrax scaffold features a unique microstructure and microporosity that are optimized for bone formation, and that its AttraX surface technology drives the differentiation of mesenchymal stem cells into bone-forming osteoblasts without the need for added growth factors.
“AttraX scaffold was easy to use and maintained excellent handling characteristics throughout the procedures. The material was highly absorbent of bone marrow aspirate and easily cut or molded to the desired shape. After experiencing AttraX scaffold firsthand, I am very pleased to offer this scientifically advanced ceramic bone graft to my spinal fusion patients,” Dr. J. Burkus of Columbus, Ga.’s Hughston Clinic, who performed the first clinical cases with the scaffold, said in a prepared statement.
The newly launched biologics scaffold is available in strips. blocks and morsels, the company said. The product is intended to complement the company’s AttraX Putty product line.
“With AttraX Scaffold we have enhanced the NuVasive Biologics portoflio to better serve our surgeons. We are delivering the only ceramic-collagen scaffold for spine surgery that achieves desirable handling characteristics, elicits an osteogenic response from the body’s cells and performs with remarkable fusion rates. Surface optimization represents the next leap forward in ceramic bone grafting technology and has the potential to deliver outstanding clinical outcomes for surgeons and their patients,” NuVasive corp dev, strategy and tech exec VP Matt Link said in a press release.
Early last month, NuVasive posted first quarter earnings that missed the Street on non-GAAP earnings per share and saw profits turn to losses.
